Lognevity drugs might not cost a fortune

At the World Science Festival, Harvard University professor and co-founder of Sirtris Pharmaceuticals talked about a molecule that targets a gene linked to longevity at a discussion on the science of longevity.  Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.